DOCSLIB.ORG

US5098714.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US5098714.Pdf |||||||||||| USOO5098714A United States Patent (19) 11 Patent Number: 5,098,714 Wright et al. (45) Date of Patent: Mar. 24, 1992 54) OSMOTIC, ORAL DOSAGE FORM FOR 4,309,996 l/1982 Theeuwes ........................... 28/260 FERTILITY CONTROL 4,320,759 3/1982 Theeuwes ........................... 128/260 o 4,449,983 5/1983 Cortese et al. ...................... 604/892 75 Inventors: Jeri D. Wright, Dublin; Jerry D. 4,772,474 9/1988 Eckenhoff et al. ................. 424/465 Childers, Fremont; Brian L. Barclay, 4,814,182 3/1989 Graham et al. ..................... 424/484 Sunnyvale; Patrick S. Wong, Palo Alto; Linda E. Atkinson, Portola OTHER PUBLICATIONS Valley, all of Calif. Wurster, Dale E.; J. Am. Pharm. Assn., Sci. Ed., vol. 49 73)73 AssiAssignee : ALZA Corporation,ion, Palo Alto, Calif.Cali Wurster,(1960), pp. Dale 82-4. E.; J. An. Pharm. Assoc., Sci. Ed., vol. 48 21 Appl. No.: 437,480 (1959), pp. 451-54. 22 Filed: Nov. 16, 1989 - The Pharmacological Basis of Therapeutics, by Goodman & Gilman, 7th Ed., (1985), pp. 1430-39. 5) Int. C.’................................................ A61K 9/24 52 U.S. Cl. .................................... 424/473; 424/471; Primary Examiner-Thurman K. Page 424/472 Assistant Examiner-Leon R. Horne 58 Field of Search ........................ 424/473, 471, 472 Attorney, Agent, or Firm-Paul L. Sabatine; Edward L. (56) References Cited Mandell; Jacqueline S. Larson U.S. PATENT DOCUMENTS (57) ABSTRACT 2,799,241 7/1957 Wurster ................................ 1824. An osmotic device is disclosed comprising an exterior 3,133,132 5/1964 Loeb et al. ............ 264/49 coat comprising an estrogenic and a progestogenic ste 3,845,770 1 1/1974 Theeuwes et al. .... ... 28/30 roid that are delivered immediately as a contraceptive 3,916,899 11/1975 Theeuwes et al..... ... 28/260 pair for fertility regulation in a female, and a compart 4,063,064 12/1977 Saunders et al. ..... a - 21/12 ment comprising an estrogenic steroid that is delivered 4,088,864 5/1978 Theeuwes et al..... 4,160,020 7/1979 Ayer et al............. - a a 219/260 at a controlled rate over a prolonged period of time for 4,177,256 12/1979 Michaels et al... r 3.2 fertility regulation in a female. 4,200,098 4/1980 Ayer et al..... ..125/260 4,285,987 8/1981 Ayer et al.. 427/3 9 Claims, 2 Drawing Sheets U.S. Patent Mar. 24, 1992 Sheet 1 of 2 5,098,714 FG. 4-2 U.S. Patent Mar. 24, 1992 Sheet 2 of 2 5,098,714 FG4 200.00 0. O O 0.00 6.00 TIME (HOURS) FG5 500 O O O 0.00 TIME (HOURS) 6.00 FIG6 5. 0.00 TIME (HOURS) 800 5,098,714 1. 2 progestogen in a pulsed dose followed by the rate-con OSMOTIC, ORAL DOSAGE FORM FOR trolled delivery of an estrogen over a prolonged period FERTILITY CONTROL of time for fertility control in a warm-blooded female. Another object of the invention is to provide a phar DESCRIPTION OF TECHNICAL FIELD 5 maceutically acceptable dosage form manufactured as This invention pertains to an osmotic oral dosage an osmotic dosage form that makes available initially an form useful for fertility control. The dosage form pro estrogen and a progestogen followed by sustained and vides an initial pulsed delivery of a progestogen and an controlled delivery of an estrogen. estrogen followed by a prolonged delivery of an estro Another object of the invention is to provide a novel gen. The invention concerns also a method of adminis 10 dosage form manufactured as an osmotic device that tering orally the dosage form for providing a pulsed can administer the steroids estrogen and progestogen delivery of a progestogen and an estrogen followed by immediately on entering the gastrointestinal tract for the controlled delivery of an estrogen over an extended passage to a biological receptor site to produce the period of time. desired contraceptive effect, followed by administering 15 estrogen only to the biological receptor site for the DISCLOSURE OF BACKGROUND OF THE intended effect. INVENTION Another object of the invention is to provide an os A continuous need exists for fertility control for pro motic dosage form that comprises two regimens of viding freedom for women to chose when they want to steroid administration in the same dosage form, com have children. Efforts were made, in the early 1960's, to 20 prising (1) a first regimen that administers a steroid pair satisfy the need for fertility control with the introduc comprising an estrogen and a progestogen and (2) a tion of the oral contraceptive pill comprising an estro second regimen that administers an estrogen, and genic steroid and a progestational steroid. The contra wherein the osmotic dosage form substantially elimi ceptive pill used by the prior art comprises a tablet form nates the unwanted influences of the gastrointestinal that delivers the steroids in a bulk, nonrate, uncon 25 trolled dose. In one prior art contraceptive regimen, a environment on the steroids while they reside in the tablet comprising both an estrogen and a progestin are dosage form, and also provides for instant administra administered for about three weeks, while in another tion of the steroid by the first regimen and the con modification a tablet comprising an estrogen is adminis trolled, low-dose administration or the steroid during tered for about two weeks and a tablet comprising an the second regimen. estrogen and progestin are administered for about a Another object of the invention is to provide an os week. The contraceptive steroids were delivered as an motic dosage form that can deliver a progestational oral tablet devoid of rate-controlled delivery properties steroid at a pulsed rate of delivery for substantially because the contraceptive steroids are practically insol lessening liver metabolism of the steroid. uble in aqueous fluids and, accordingly, they do not 35 Another object of the invention is to provide an os lend themselves for manufacture into a dosage form that notic dosage form that can deliver an estrogen steroid administers the steroids at a controlled and known rate in small amounts for substantially lessening the inci per unit time. dence of side effects. The contraceptive steroids, moreover, were deliv Another object of the present invention is to provide ered by the prior art in a dose unprotected from the an osmotic dosage form that can deliver a substantially changing environment of the gastrointestinal tract, with aqueous insoluble estrogen and progestogen pair at a little consideration for the steroid's pharmacological pulsed rate, and then deliver an aqueous insoluble estro and physiological effects and the accompanying disad gen at a controlled and continuous rate over time. vantages on a recipient. For example, one disadvantage Another object of the present invention is to provide associated with the prior art tablet accompanies the 45 an osmotic dosage form adapted for oral administration dose-dumping of estrogen which can lead to gastroin of an estrogen and a progestogen, which dosage form testinal disturbances, nausea, weight-gain, edema, and comprises an external pulse released coat comprising an an increase in the incidence of thrombophelibitis and estrogen and a progestogen, and a compartment con associated cardiovascular disorders. Also, the prior art prising a first composition comprising an estrogen and a tablet does not provide for the fast release of a progesta 50 contacting second expandable composition, which com tional steroid for avoiding liver metabolism of the ste positions operate together for the controlled administra roid and the subsequent delivery of an estrogen in small tion of an estrogen over time. continuous doses for lessening the incidence of side Another object of the present invention is to provide effects in the recipient. The oral contraceptives are a complete oral contraceptive regimen useful for disclosed in The Pharmacological Basis of Therapeutics, 55 women of childbearing age which regimen comprises by Goodman and Gilman, 7th Ed., pages 1430 to 1439 an osmotic dosage form and a method of contraception, (1985), published by Macmillian Publishing Company. the use of which osmotic dosage form and method of contraception requires intervention only for initiation DISCLOSURE OF OBJECTS OF THE of the contraceptive regimen. INVENTION Another object of the invention is to provide a com Accordingly, in view of the above presentation, it is position of matter comprising an estrogen, a progesto an immediate object of this invention to provide a dos gen and a cellulose polymer, which composition can be age form comprising an estrogen and a progestogen that externally stored on and dispensed from an osmotic can be administered for fertility control, and which device for the purpose of fertility control. dosage form substantially overcomes the disadvantages 65 Another object of the invention is to provide a and omissions associated with the prior art. method for producing contraception by orally adminis Another object of the present invention is to provide tering an estrogen and a progestogen to a warm a dosage form for co-administering an estrogen and a blooded animal desiring fertility control. 5,098,714 3 4. Another object of the invention is to provide a con 14 that connects internal compartment 13 with the exte traceptive regimen comprising eighteen to twenty-three rior of dosage form 10. Dosage form 10 can comprise dosage forms, which dosage forms deliver a pulsed dose more than one exit means 14. Wall 12 of dosage form 10 of a progestational and estrogenic steroid followed by a comprises in at least a part a semipermeable composi continuous dose of an estrogenic steroid. tion that is permeable to the passage of an exterior fluid Other objects, features, and advantages of the inven present in the environment of use.
Load more

Recommended publications
  • Estrone with Pipera- with an Anabolic Steroid and a Progestogen for Osteoporosis
    Estradiol/Ethinylestradiol 2101 Estrapronicate (rINN) menopausal atrophic vaginitis and kraurosis vulvae. A dose of Estrapronicato; Estrapronicatum. Oestradiol 17-nicotinate 3- 500 micrograms may be given as a 0.01% or 0.1% cream or as a pessary; initial treatment may be given once daily, then reduced propionate. O to twice each week. NH CH3 Эстрапроникат Estriol has also been given orally for infertility (p.2080) caused HN C27H31NO4 = 433.5. by poor cervical penetration, in a dose of 0.25 to 1 mg daily on H CAS — 4140-20-9. days 6 to 15 of the menstrual cycle. O Estriol succinate has also been given orally in the treatment of HO HH menopausal disorders. The sodium succinate salt has been used S N parenterally in the treatment of haemorrhage and thrombocyto- O penia. O Preparations Pharmacopoeias. In Br. and US. BP 2008: Estriol Cream. BP 2008 (Estropipate). A white or almost white crystalline pow- Proprietary Preparations (details are given in Part 3) O O der. Very slightly soluble in water, in alcohol, in chloroform, and Arg.: Colpoestriol; Orgestriol; Austral.: Ovestin; Austria: Ortho-Gynest; in ether. H3C Ovestin; Styptanon; Belg.: Aacifemine; Ortho-Gynest; Braz.: Estriopax; Hormocervix; Hormoniol; Ovestrion; Styptanon; Chile: Ovestin; Sina- USP 31 (Estropipate). A white to yellowish-white fine crystal- pause; Vacidox; Cz.: Ortho-Gynest; Ovestin; Denm.: Ovestin; Fin.: Oves- line powder, odourless or may have a slight odour. Very slightly H tin; Pausanol; Fr.: Gydrelle; Physiogine; Trophicreme; Ger.: Cordes Estriol; soluble in water, in alcohol, in chloroform, and in ether; soluble Gynasan†; OeKolp; Oestro-Gynaedron M; Ortho-Gynest; Ovestin; Syna- 1 in 500 of warm alcohol; soluble in warm water.
    [Show full text]
  • Depo-Estradiol (Estradiol Cypionate) Injection
    Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Depo-Estradiol (estradiol cypionate) injection Override(s) Approval Duration Prior Authorization 1 year Medications Depo-Estradiol (estradiol cypionate) injection APPROVAL CRITERIA Requests for Depo-Estradiol (estradiol cypionate) injection may be approved when the following criteria are met: I. Individual is using to treat moderate to severe vasomotor symptoms associated with menopause; OR II. Individual has been diagnosed with hypoestrogenism due to hypogonadism; OR III. Individual has a diagnosis of gender dysphoria or gender identity disorder (WPATH 2012, Endocrine Society 2017) ; AND IV. Individual is 16 years of age or older; AND V. The goal of treatment is male-to-female gender reassignment. Requests for Depo-Estradiol (estradiol cypionate) injection may not be approved for any of the following: I. Individual has undiagnosed abnormal genital bleeding; OR II. Individual has known or suspected cancer of the breast; OR III. Individual has known or suspected estrogen-dependent neoplasia; OR IV. Individual has active deep vein thrombosis, pulmonary embolism or history of these conditions; OR V. Individual has active or recent (within the past year) arterial thromboembolic disease (such as stroke or myocardial infarction); OR VI. Individual has liver dysfunction or disease. PAGE 1 of 2 02/24/2020 New Program Date 02/24/2020 CRX-ALL-0519-20 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
    [Show full text]
  • Pms-ESTRADIOL VALERATE INJECTION
    PRODUCT MONOGRAPH Prpms-ESTRADIOL VALERATE INJECTION Estradiol Valerate 10 mg/mL Estrogen PHARMASCIENCE INC. Date of Revision: 6111 Royalmount Avenue, Suite 100 June 30, 2009 Montreal, Quebec H4P 2T4 Control Number: 120632 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION……………………………...3 SUMMARY PRODUCT INFORMATION……………………………………….3 INDICATIONS AND CLINICAL USE…………………………………………...3 CONTRAINDICATIONS…………………………………………………………4 WARNINGS AND PRECAUTIONS…………………………………….……….5 ADVERSE REACTIONS………………………………………………………...13 DRUG INTERACTIONS………………………………………………………...15 DOSAGE AND ADMINISTRATION…………………………………………...17 OVERDOSAGE………………………………………………………………….19 ACTION AND CLINICAL PHARMACOLOGY……………………………….19 STORAGE AND STABILITY…………………………………………………...22 DOSAGE FORMS, COMPOSITION AND PACKAGING……………………..22 PART II: SCIENTIFIC INFORMATION…………………………………………….23 PHARMACEUTICAL INFORMATION………………………………………...23 CLINICAL TRIALS……………………………………………………………...24 DETAILED PHARMACOLOGY………………………………………………..24 REFERENCES…………………………………………………………………...25 PART III: CONSUMER INFORMATION……………………………………………………27 2 PRODUCT MONOGRAPH Prpms- ESTRADIOL VALERATE INJECTION (Estradiol Valerate) 10 mg/mL PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Dosage Form / Strength Clinically Relevant Nonmedicinal Administration Ingredients Intramuscular Injection / 10 mg/mL Sesame Oil For a complete listing see Dosage Forms, Composition and Packaging section. INDICATIONS AND CLINICAL USE pms-ESTRADIOL VALERATE INJECTION is indicated in the treatment of: I. amenorrhea (primary
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • To See References
    Longevity & Bioidentical Hormones Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009 May;94(5):1732-9. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871-6. Besson A, Salemi S, Gallati S, et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003 Aug;88(8):3664- 7. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004 Jan;89(1):114-120. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004 Jan 27;62(2):188-193. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-701. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-3318. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III).
    [Show full text]
  • Drug and Chemical Reference Guideline
    WISCONSIN DEPARTMENT OF AGRICULTURE, TRADE AND CONSUMER PROTECTION DIVISION OF FOOD AND RECREATIONAL SAFETY TITLE: Drug and Chemical Reference Guideline Document #: Replaces: New Revision Date: 1/21/2020 Page 1 of 6 General Guidelines: These drugs and substances are not to be used or • Drugs and administration equipment stored to not stored on dairy farms. These drugs are not eligible for contaminate milk or milk contact surfaces ELU privileges by veterinarians. • Non-lactating drugs separated from lactating drugs • Chloramphenicol using separate shelves or cabinets • Clenbuterol • Drugs properly labeled (see label requirements • Colloidal Silver below) • Diethylstilbestrol (DES) • Locked drug cabinets must be made accessible for • Dimethysulfoxide (DMSO) inspection • Dimetridazole • Drugs for animal species other than cattle must not • Dipyrone (Novine, No Pain) be stored in dairy facility • Estradiol Cypionate (ECP) • All bottles or packages in case lots properly labeled • Fluoroquinolones (sarafloxacin-Saraflox, orbafloxacin-Orbox, danofloxacin mesylate-A 180) Drug Labeling Requirements: • Furazolidone, Nitrofurazone, other Nitrofurans OTC Drugs: (over the counter) • Glycopeptides (vancomycin) • Name of Drug • Iononphores (Lasalocid) permitted for non-lactating • Active ingredients • Ipronidazole • Directions for use • Metronidazole and other Nitroimidazoles • Withholding/withdrawal or discard time for meat or • Phenylbutazone, “bute” (prohibited in dairy animals milk (even if zero) 20 months of age or older - no ELU allowed.) • Name
    [Show full text]
  • Estradiol Acetate Vaginal Ring) Rx Only
    NDA 21-367/S-002 Page 3 PRESCRIBING INFORMATION Femring® (estradiol acetate vaginal ring) Rx Only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (See WARNINGS, Cardiovascular disorders and Dementia.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms, Breast cancer.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten Et Al
    US007723320B2 (12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten et al. (45) Date of Patent: May 25, 2010 (54) USE OF ESTROGEN COMPOUNDS TO DE 23,36434. A 4, 1975 INCREASE LIBDO IN WOMEN WO WO96 O3929 A 2, 1996 (75) Inventors: Evert Johannes Bunschoten, Heesch OTHER PUBLICATIONS (NL); Herman Jan Tijmen Coelingh Bennink, Driebergen (NL); Christian Holinka CF et al: “Comparison of Effects of Estetrol and Taxoxifen Franz Holinka, New York, NY (US) with Those of Estriol and Estradiol on the Immature Rat Uterus'; Biology of Reproduction; 1980; pp. 913-926; vol. 22, No. 4. (73) Assignee: Pantarhei Bioscience B.V., Al Zeist Holinka CF et al; "In-Vivo Effects of Estetrol on the Immature Rat (NL) Uterus'; Biology of Reproduction; 1979: pp. 242-246; vol. 20, No. 2. Albertazzi Paola et al.; "The Effect of Tibolone Versus Continuous Combined Norethisterone Acetate and Oestradiol on Memory, (*) Notice: Subject to any disclaimer, the term of this Libido and Mood of Postmenopausal Women: A pilot study': Data patent is extended or adjusted under 35 base Biosis "Online!; Oct. 31, 2000: pp. 223-229; vol. 36, No. 3; U.S.C. 154(b) by 1072 days. Biosciences Information Service.: Philadelphia, PA, US. Visser et al., “In vitro effects of estetrol on receptor binding, drug (21) Appl. No.: 10/478,264 targets and human liver cell metabolism.” Climacteric (2008) 11(1) Appx. II: 1-5. (22) PCT Filed: May 17, 2002 Visser et al., “First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.” Climacteric (2008) 11(1): (86).
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]